Targeted therapy for multiple myeloma: an overview on CD138-based strategies
Open Access
- 9 April 2024
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1370854
Abstract
Multiple myeloma (MM) is an incurable hematological disease characterized by the uncontrolled growth of plasma cells primarily in the bone marrow. Although its treatment consists of the administration of combined therapy regimens mainly based on immunomodulators and proteosome inhibitors, MM remains incurable, and most patients suffer from relapsed/refractory disease with poor prognosis and survival. The robust results achieved by immunotherapy targeting MM-associated antigens CD38 and CD319 (also known as SLAMF7) have drawn attention to the development of new immune-based strategies and different innovative compounds in the treatment of MM, including new monoclonal antibodies, antibody-drug conjugates, recombinant proteins, synthetic peptides, and adaptive cellular therapies. In this context, Syndecan1 (CD138 or SDC1), a transmembrane heparan sulfate proteoglycan that is upregulated in malignant plasma cells, has gained increasing attention in the panorama of MM target antigens, since its key role in MM tumorigenesis, progression and aggressiveness has been largely reported. Here, our aim is to provide an overview of the most important aspects of MM disease and to investigate the molecular functions of CD138 in physiologic and malignant cell states. In addition, we will shed light on the CD138-based therapeutic approaches currently being tested in preclinical and/or clinical phases in MM and discuss their properties, mechanisms of action and clinical applications.Keywords
This publication has 213 references indexed in Scilit:
- Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosisCancer Medicine, 2023
- Insights into B‐cell ontogeny inferred from human immunologyEuropean Journal of Immunology, 2023
- Clinical significance of circulatory microRNA-203 in serum as novel potential diagnostic marker for multiple myelomaJournal of Cancer Research and Clinical Oncology, 2019
- Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple MyelomaJAMA Oncology, 2018
- Strategies to Reduce the Immunogenicity of Recombinant ImmunotoxinsThe American Journal of Pathology, 2018
- Shed proteoglycans in tumor stromaCell and tissue research, 2016
- Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patientsTumor Biology, 2012
- Activin A stimulates IκB‐α/NFκB and rank expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursorsJournal of Cellular Biochemistry, 2003
- Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myelomaCancer, 2002
- Efficacy and toxicity of plasma-cell-reactive monoclonal antibodies B-B2 and B-B4 and their immunotoxinsCancer Immunology, Immunotherapy, 1996